<DOC>
	<DOC>NCT00622063</DOC>
	<brief_summary>To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501</brief_summary>
	<brief_title>An Extension Study for Patients Previously Treated With ARQ 501</brief_title>
	<detailed_description />
	<mesh_term>Beta-lapachone</mesh_term>
	<criteria>Signed written informed consent Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment Have not received previous treatment with ARQ 501 under a treatment protocol Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>cancer, solid tumor</keyword>
</DOC>